Drugmakers pull back after Covid boom, planning to cut costs as they prepare for industry’s next era

Drew Armstrong

Executive Editor

Jaimy Lee

Deputy Editor

Reynald Castañeda

Deputy Editor

Biopharma companies whose Covid-19 drugs and vaccines created an unprecedented flood of new revenue and profits are now pulling back on the huge investments they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drugmakers pull back after Covid boom, planning to cut costs as they prepare for industry’s next era

Drew Armstrong

Executive Editor

Jaimy Lee

Deputy Editor

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Drug­mak­ers pull back af­ter Covid boom, plan­ning to cut costs as they pre­pare for in­dus­try’s next era

Executive Editor

Deputy Editor

Deputy Editor

Sign up to read this article for free.

Drugmakers pull back after Covid boom, planning to cut costs as they prepare for industry’s next era